Diagnosis Articles

?️ Articles on positive diagnosis of NASH/NAFLD; there should be hepatic steatosis by imaging or histology or no significant alcohol consumption.

Noninvasive tests for NAFLD: where are we now?

Authors: Alnimer L and Noureddin M
Published in Clinical and Molecular Hepatology (April 2023)
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Read More

Proteo-Transcriptomics for at-Risk NASH: the Future of Non-Invasive Risk Assessments?

Authors: Ajmera V
Published in Nature Metabolism (April 2023)
Proteo-transcriptomic analyses offer a promising approach for precise NASH risk assessment. A predictive model based on protein levels and clinical variables demonstrates 79% accuracy. This innovative method holds potential for developing blood-based diagnostic tools. Further testing in diverse populations is necessary to validate its efficacy.
Read More

NAFLD and NASH Occurring After Liver Transplantation: a Review

Authors: Lonardo A, Mantovani A, Petta S, et al.
Published in Nat Rev Endocrinol 2023
Recurrence of NASH/NAFLD after liver transplantation requires attention. Factors include weight gain, post-transplant diabetes, and immunosuppressant drugs. Donor-related genetic risk factors also contribute. A multidisciplinary approach is essential for prevention and management.
Read More

Inflammation in non-alcoholic fatty liver disease: Part 2

Authors: Wiering L & Tacke F
Published in J Endocrinol 2022
Non-alcoholic fatty liver disease (NAFLD) has a more progressive form, non-alcoholic steatohepatitis (NASH). In both conditions, inflammation is a key driver of the pathogenesis. Current treatments mostly focus on promoting weight loss (through encouraging lifestyle changes, or, if necessary, bariatric surgery) and improving comorbidities through pharmacotherapy, such as type 2 diabetes.
Read More

FIB-4 and NFS: which performance?

Authors: Castellana M, Donghia R, Guerra V, et al.
Published in Am J Gastroenterol 2021
M. Castellana et al. (National Institute of Gastroenterology "Saverio de Bellis," Research Hospital, Italy) conducted a meta-analysis to assess the performance of the FIB-4 and NFS scores, the 2 most common non-invasive tools, for the appropriate selection of subjects with AF for biopsy. A total of 18 studies evaluating 12,604 subjects were included...
Read More

Enhanced liver fibrosis test and recognition of liver fibrosis

Authors: Younossi ZM, Felix S, Jeffers T, et al.
Published in JAMA Netw Open 2021
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system's outpatient liver clinic from 2001 to 202 in order to determine the performance of the enhanced liver fibrosis (ELF) test as a non-invasive test for assessment of liver fibrosis among patients with NAFLD...
Read More

NAFLD unawareness in US adults

Authors: Alqahtani SA, Paik JM, Biswas R, et al.
Published in Mol Metab 2021
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD...
Read More

Identifying patients with high-risk NASH: three ultrasound markers

Authors: Sugimoto K, Lee DH, Lee JY, et al.
Published in Radiology 2021
Identifying patients with high-risk-NASH who are candidates for pharmacologic therapy remains a challenge. K. Sugimoto et al. (Tokyo Medical University, Japan) aimed to develop a score to identify patients with a NAFLD activity score of 4 or greater and clinically significant fibrosis...
Read More

Detection of HCC in patients with NAFLD

Authors: Caviglia GP, Armandi A, Rosso C, et al.
Published in Cancers (Basel) 2021
Current surveillance strategy for patients with NAFLD at risk of HCC development is unsatisfactory. G. P. Caviglia et al. (National University Health System, and Yong Loo Lin School of Medicine, National University of Singapore) aimed to investigate the diagnostic accuracy of alpha-fetoprotein (AFP), protein induced by vitamin K...
Read More